On September 12 th, Bright Minds Biosciences announced the initiation of the BREAKTHROUGH Study, an open-label Phase 2 clinical trial evaluating the safety, tolerability, and efficacy of BMB-101 in ...
In August 2023, the Canadian Drug Agency (CDA) - which Ontario funds to review new drugs - recommended that Xcopri be publicly funded by all ... For these difficult-to-treat cases, cenobamate is ...